Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece

BMC Health Services Research

Volumn 14, Issue 1, 2014, Pages

  Tzanetakos, Charalampos ^a   Melidonis, Andreas ^b   Verras, Christos ^b   Kourlaba, Georgia ^c   Maniadakis, Nikos ^a  

^a NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^b TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^c AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

Author keywords

Cost effectiveness; Greece; Liraglutide; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; LIRAGLUTIDE; PEPTIDE; PYRAZINE DERIVATIVE; SITAGLIPTIN; TRIAZOLE DERIVATIVE; VENOM;

ADULT; ANALOGS AND DERIVATIVES; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; ECONOMICS; FEMALE; GREECE; HUMAN; MALE; MIDDLE AGED;

ADULT; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GREECE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PEPTIDES; PYRAZINES; TRIAZOLES; VENOMS;

EID: 84907915468     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-14-419     Document Type: Article

References (36)

1. The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives. Chen L, Magliano DJ, Zimmet PZ, Nat Rev Endocrinol 2012 8 228 236
2. Assessing the impact of complications on the costs of Type II diabetes. Williams R, Van Gaal L, Lucioni C, Board C-A, Diabetologia 2002 45 13 S17 10.1007/s00125-002-0859-9 12136406
3. The epidemiology of Type 2 diabetes mellitus in Greek adults: the ATTICA study. Panagiotakos DB, Pitsavos C, Chrysohoou C, Stefanadis C, Diabet Med 2005 22 1581 1588 10.1111/j.1464-5491.2005.01731.x 16241925
4. International Diabetes Federation, IDF Diabetes Atlas Brussels, Belgium: International Diabetes Federation 6 2013 Accessed March 30, 2014 [ http://www.idf.org/diabetesatlas ]
5. Estimating the direct cost of Type 2 diabetes in Greece: the effects of blood glucose regulation on patient cost. Athanasakis K, Ollandezos M, Angeli A, Gregoriou A, Geitona M, Kyriopoulos J, Diabet Med 2010 27 679 684 10.1111/j.1464-5491.2010.03004.x 20546287
6. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR, Diabetologia 2012 55 1577 1596 10.1007/s00125-012-2534-0 22526604
7. Management guidelines for a diabetic patient. Hellenic Diabetes Association, Accessed September 15, 2013 [ http://www.ede.gr/ ]
8. An overview of the pharmacokinetics, efficacy and safety of liraglutide. Bode B, Diabetes Res Clin Pract 2012 97 27 42 10.1016/j.diabres.2011.12.015 22245694
9. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA, Curr Med Res Opin 2004 20 Suppl 1 27 S40 15324514
10. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA, Curr Med Res Opin 2004 20 Suppl 1 5 S26
11. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Sondergaard RE, Davies M, Group L-D-S, Lancet 2010 375 1447 1456 10.1016/S0140-6736(10)60307-8 20417856
12. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L, Group L-S, Lancet 2009 374 39 47 10.1016/S0140-6736(09)60659-0 19515413
13. Trends in the management of type 2 diabetes and its prescription drug costs in Greece (1998 & 2006). Liatis S, Thomakos P, Papaoikonomou S, Papazafeiropoulou A, Giannakopoulos N, Karagiaouri E, Sotiropoulos A, Bousboulas S, Melidonis A, Pappas S, Katsilambros N, Exp Clin Endocrinol Diabetes 2009 117 505 510 10.1055/s-0029-1225338 19629932
14. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simo R, Liraglutide E, Action in Diabetes 5 met SUSG, Diabetologia 2009 52 2046 2055 10.1007/s00125-009-1472-y 19688338
15. Drug Price Bulletin. Greek Ministry of Health, Accessed September 15, 2013 [ http://www.yyka.gov.gr/ ]
16. Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece. Athanasakis K, Fragoulakis V, Tsiantou V, Masaoutis P, Maniadakis N, Kyriopoulos J, Clin Ther 2012 34 446 456 10.1016/j.clinthera.2012.01.005 22289279
17. Insurance coverage for the treatment of patients with chronic renal insufficiency. Adoption of economic assessment by the Institute of Social Insurance (IKA). Souliotis K, Papavasilopoulou M, Konstantinidou C, Spanakis αμ Apostolakis μ Iatrou C, Arch Hell Med 2009 26 5 668 677
18. Economic evaluation of hemodialysis: implications for technology assessment in Greece. Kaitelidou D, Ziroyanis PN, Maniadakis N, Liaropoulos LL, Int J Technol Assess Health Care 2005 21 40 46 15736513
19. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis. Kourlaba G, Fragoulakis V, Maniadakis N, Appl Health Econ Health Policy 2012 10 261 271 10.2165/11633820-000000000-00000 22667992
20. Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece. Kourlaba G, Fragoulakis V, Maniadakis N, Appl Health Econ Health Policy 2012 10 331 342 10.1007/BF03261867 22853743
21. Sidiropoulos S, Estimating the Cost of Renal Transplantation in Greece Thesis: University of Macedonia, Business Administration Department 2009
22. Inflation rates. Hellenic Statistical Authority (EL. STAT.), Accessed September 30, 2013 [ http://www.statistics.gr/portal/page/portal/ESYE ]
23. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus. Davies MJ, Chubb BD, Smith IC, Valentine WJ, Diabet Med 2012 29 313 320 10.1111/j.1464-5491.2011.03429.x 21883438
24. Choosing interventions that are Cost Effective (WHO-CHOICE): cost-effectiveness thresholds. World Health Organisation (WHO), Accessed December 10, 2013 [ http://www.who.int/choice/costs/CER-thresholds/en/index.html ]
25. World Economic Outlook Database. International Monetary Fund (IMF), Accessed December 10, 2013 [ http://www.imf.org/external/pubs/ft/weo/2012/02/weodata/index.aspx ]
26. Economic evaluation of treatment strategies for patients suffering acute myocardial infarction in Greece. Maniadakis N, Kaitelidou D, Siskou O, Spinthouri M, Liaropoulos L, Fragoulakis B, Hatzikou M, Alexopoulosi D, Hellenic J Cardiol 2005 46 212 221 15981557
27. Guidance on the Use of long-Acting Insulin Analogues for the treatment of Diabetes-Insulin Glargine (TA53). National Institute for Health and Clinical Excellence (NICE), Accessed September 30, 2013 [ http://guidance.nice.org.uk/TA53/Guidance/pdf/English ]
28. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Pratley RE, Nauck MA, Bailey T, Montanya E, Filetti S, Garber AJ, Thomsen AB, Furber S, Davies M, Group L-D-S, Diabetes Care 2012 35 1986 1993 10.2337/dc11-2113 22851600
29. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Pratley R, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Garber A, Thomsen AB, Hartvig H, Davies M, Group L-D-S, Int J Clin Pract 2011 65 397 407 10.1111/j.1742-1241.2011.02656.x 21355967
30. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis. Lee WC, Samyshkin Y, Langer J, Palmer JL, J Med Econ 2012 15 Suppl 2 28 37 22834986
31. Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin. Mezquita Raya P, Perez A, Ramirez de Arellano A, Briones T, Hunt B, Valentine WJ, Diabetes Ther 2013 4 417 430 10.1007/s13300-013-0044-9 24132613
32. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States. Lee WC, Conner C, Hammer M, Clin Ther 2010 32 1756 1767 10.1016/j.clinthera.2010.08.010 21194600
33. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents. Valentine WJ, Palmer AJ, Lammert M, Langer J, Brandle M, Clin Ther 2011 33 1698 1712 10.1016/j.clinthera.2011.09.022 22018679
34. Effects of intensive glucose lowering in type 2 diabetes. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT, N Engl J Med 2008 358 2545 2559 18539917
35. Glucose control and vascular complications in veterans with type 2 diabetes. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD, N Engl J Med 2009 360 129 139 10.1056/NEJMoa0808431 19092145
36. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F, N Engl J Med 2008 358 2560 2572 18539916